Physicians’ attitudes towards disclosure of payments from pharmaceutical companies in a nationwide voluntary transparency database: a cross-sectional survey
Objectives To investigate German physicians’ attitudes towards and experiences with voluntary disclosure of payments by pharmaceutical companies in a public database and their impact on future decisions for or against disclosure.Design A national cross-sectional survey conducted in 2018 among physic...
| Príomhchruthaitheoirí: | , , , , |
|---|---|
| Formáid: | Alt |
| Teanga: | English |
| Foilsithe / Cruthaithe: |
BMJ Publishing Group
2022-06-01
|
| Sraith: | BMJ Open |
| Rochtain ar líne: | https://bmjopen.bmj.com/content/12/6/e055963.full |
| _version_ | 1826853010621333504 |
|---|---|
| author | Marlene Stoll Lara Hubenschmid Cora Koch Klaus Lieb Boris Egloff |
| author_facet | Marlene Stoll Lara Hubenschmid Cora Koch Klaus Lieb Boris Egloff |
| author_sort | Marlene Stoll |
| collection | DOAJ |
| description | Objectives To investigate German physicians’ attitudes towards and experiences with voluntary disclosure of payments by pharmaceutical companies in a public database and their impact on future decisions for or against disclosure.Design A national cross-sectional survey conducted in 2018 among physicians who voluntarily disclosed at least one payment in the German transparency regulation.Setting Retrospective paper-pencil questionnaire about attitudes towards and experiences with voluntary payment disclosures in the first (2015) and second (2016) years of the German transparency regulation.Participants German physicians who disclosed either in the first year only, the second year only, or in both years of the transparency regulation.Primary outcomes (1) The probability to disclose in 2016, predicted by physicians’ experience of reactions from others in 2015, descriptive norms and attitudes towards transparency; (2) Frequency and (3) Content of reactions from others in 2015 compared with 2016.Results Data of 234 respondents were analysed (n=42, 45 and 147 physicians who disclosed in 2015, 2016 or both years, respectively). The probability to disclose in 2016 was not predicted by perceived reactions, norms or attitudes towards transparency (p>0.01). Most participants reported not to have received any reactions by patients (190/234, 81%), colleagues (128/234, 55%) or the private environment (153/234, 65%). Neither frequency nor content of reactions differed between the first and second years (scale 1–5; frequency: Mdn2015,2016 = 1.33 vs 1.00, rb=−0.17, p>0.01; content: Mdn2015,2016 = 3.00 vs 3.00, rb=0.19, p>0.01). However, media reporting, fear of reputational damage and a feeling of being defamed were mentioned as reasons for non-disclosure.Conclusions While confirmatory analyses did not provide significant results, descriptive analyses showed that participants who voluntarily disclose payments mainly do not experience any reactions towards their disclosures but report fears about losing their reputation due to disclosures. |
| first_indexed | 2024-12-12T14:07:10Z |
| format | Article |
| id | doaj.art-86c4dc25299144528db3a7a4265684a6 |
| institution | Directory Open Access Journal |
| issn | 2044-6055 |
| language | English |
| last_indexed | 2025-02-16T17:18:13Z |
| publishDate | 2022-06-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | BMJ Open |
| spelling | doaj.art-86c4dc25299144528db3a7a4265684a62025-01-28T00:05:12ZengBMJ Publishing GroupBMJ Open2044-60552022-06-0112610.1136/bmjopen-2021-055963Physicians’ attitudes towards disclosure of payments from pharmaceutical companies in a nationwide voluntary transparency database: a cross-sectional surveyMarlene Stoll0Lara Hubenschmid1Cora Koch2Klaus Lieb3Boris Egloff4Department of Psychiatry and Psychotherapy, University Medical Center Mainz, Mainz, GermanyLeibniz Institute for Resilience Research (LIR) gGmbH, Mainz, GermanyDepartment of Neurology and Neurophysiology, Medical Center - University of Freiburg, Freiburg, GermanyPsychiatry and Psychotherapy, University Medical Center Mainz, Mainz, GermanyDepartment of Psychology, Johannes Gutenberg University Mainz, Mainz, GermanyObjectives To investigate German physicians’ attitudes towards and experiences with voluntary disclosure of payments by pharmaceutical companies in a public database and their impact on future decisions for or against disclosure.Design A national cross-sectional survey conducted in 2018 among physicians who voluntarily disclosed at least one payment in the German transparency regulation.Setting Retrospective paper-pencil questionnaire about attitudes towards and experiences with voluntary payment disclosures in the first (2015) and second (2016) years of the German transparency regulation.Participants German physicians who disclosed either in the first year only, the second year only, or in both years of the transparency regulation.Primary outcomes (1) The probability to disclose in 2016, predicted by physicians’ experience of reactions from others in 2015, descriptive norms and attitudes towards transparency; (2) Frequency and (3) Content of reactions from others in 2015 compared with 2016.Results Data of 234 respondents were analysed (n=42, 45 and 147 physicians who disclosed in 2015, 2016 or both years, respectively). The probability to disclose in 2016 was not predicted by perceived reactions, norms or attitudes towards transparency (p>0.01). Most participants reported not to have received any reactions by patients (190/234, 81%), colleagues (128/234, 55%) or the private environment (153/234, 65%). Neither frequency nor content of reactions differed between the first and second years (scale 1–5; frequency: Mdn2015,2016 = 1.33 vs 1.00, rb=−0.17, p>0.01; content: Mdn2015,2016 = 3.00 vs 3.00, rb=0.19, p>0.01). However, media reporting, fear of reputational damage and a feeling of being defamed were mentioned as reasons for non-disclosure.Conclusions While confirmatory analyses did not provide significant results, descriptive analyses showed that participants who voluntarily disclose payments mainly do not experience any reactions towards their disclosures but report fears about losing their reputation due to disclosures.https://bmjopen.bmj.com/content/12/6/e055963.full |
| spellingShingle | Marlene Stoll Lara Hubenschmid Cora Koch Klaus Lieb Boris Egloff Physicians’ attitudes towards disclosure of payments from pharmaceutical companies in a nationwide voluntary transparency database: a cross-sectional survey BMJ Open |
| title | Physicians’ attitudes towards disclosure of payments from pharmaceutical companies in a nationwide voluntary transparency database: a cross-sectional survey |
| title_full | Physicians’ attitudes towards disclosure of payments from pharmaceutical companies in a nationwide voluntary transparency database: a cross-sectional survey |
| title_fullStr | Physicians’ attitudes towards disclosure of payments from pharmaceutical companies in a nationwide voluntary transparency database: a cross-sectional survey |
| title_full_unstemmed | Physicians’ attitudes towards disclosure of payments from pharmaceutical companies in a nationwide voluntary transparency database: a cross-sectional survey |
| title_short | Physicians’ attitudes towards disclosure of payments from pharmaceutical companies in a nationwide voluntary transparency database: a cross-sectional survey |
| title_sort | physicians attitudes towards disclosure of payments from pharmaceutical companies in a nationwide voluntary transparency database a cross sectional survey |
| url | https://bmjopen.bmj.com/content/12/6/e055963.full |
| work_keys_str_mv | AT marlenestoll physiciansattitudestowardsdisclosureofpaymentsfrompharmaceuticalcompaniesinanationwidevoluntarytransparencydatabaseacrosssectionalsurvey AT larahubenschmid physiciansattitudestowardsdisclosureofpaymentsfrompharmaceuticalcompaniesinanationwidevoluntarytransparencydatabaseacrosssectionalsurvey AT corakoch physiciansattitudestowardsdisclosureofpaymentsfrompharmaceuticalcompaniesinanationwidevoluntarytransparencydatabaseacrosssectionalsurvey AT klauslieb physiciansattitudestowardsdisclosureofpaymentsfrompharmaceuticalcompaniesinanationwidevoluntarytransparencydatabaseacrosssectionalsurvey AT borisegloff physiciansattitudestowardsdisclosureofpaymentsfrompharmaceuticalcompaniesinanationwidevoluntarytransparencydatabaseacrosssectionalsurvey |